Filter By Category
Archives
Share on -
ATIRMOCICLIB
Generic Name: ATIRMOCICLIB
ABSTRACT -
Atirmociclib (PF-07220060) is an investigational oral cyclin-dependent kinase 4 (CDK4)-selective inhibitor. By inhibiting CDK4/cyclin D signaling, it is intended to reduce retinoblastoma protein phosphorylation and arrest susceptible tumor cells in the G1 phase. It is a small molecule with molecular formula C22H27ClFN5O3.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified oncology professional.
- Use should follow the clinical-trial protocol or future approved local label.
- Dose interruption, reduction, or discontinuation may be needed for toxicity.
- Blood counts and organ function should be monitored during therapy.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Nausea, diarrhea, vomiting, or appetite loss
- Fatigue, headache, or weakness
- Neutropenia, anemia, or other blood-count changes
- Rash or liver enzyme elevations
- Infections may occur when blood counts are reduced.
ALLERGIC REACTIONS -
Hypersensitivity to Atirmociclib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Atirmociclib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Atirmociclib may interact with certain medicines, protocols, vaccines, clinical conditions, or procedures. Caution is needed with:
- Strong CYP inhibitors or inducers may alter exposure if metabolism involves CYP pathways.
- Other myelosuppressive anticancer therapies can increase cytopenia risk.
- Live vaccines should generally be avoided during significant immune suppression.
- Herbal supplements and over-the-counter medicines should be reviewed.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor complete blood counts and liver function as directed.
- Assess infection symptoms promptly.
- Use contraception during and after treatment if embryo-fetal risk applies.
- Use caution in hepatic impairment or severe comorbid disease.
WARNINGS –
- Investigational anticancer kinase inhibitor: not for unsupervised use.
- Fever with neutropenia, severe diarrhea, or allergic reaction requires urgent care.
- May cause fetal harm based on mechanism and class.
- Keep out of reach of children.
Share on -
. Developed by